12.10.15
Vienna, Austria-based Miracor Medical Systems GmbH has named Antonio Colombo, M.D., FACC, FESC, FSCAI, to its scientific advisory council.
Colombo is director of the Cardiac Catheterization Laboratory at EMO GVM Centro Cuore Columbus and chief of invasive cardiology at San Raffaele Hospital, both in Milan, Italy, and visiting professor of Medicine at Columbia Medical Center in New York, N.Y. His expertise is in interventional cardiology and he has contributed significantly to today’s use of coronary stents and defined the role of intravascular ultrasound in this setting. In addition, his studies along with others have redefined adequate antiplatelet therapy after coronary stenting.
“It is with pleasure and excitement that I join the Scientific Advisory Council of Miracor,” said Colombo. “The PICSO impulse system is one of the most exciting new therapies in the area of acute myocardial infarction treatment and I also see a huge potential beyond this indication. I look forward to collaborating with the Council’s other members and to contributing significantly to the further establishment of PICSO in clinical practice and the investigation of its benefits in other indications.”
The PICSO (pressure-controlled intermittent coronary sinus occlusion) impulse system is designed for use during coronary revascularization procedures following myocardial infarction and other types of acute coronary syndrome to intermittently increase the pressure in the coronary venous system and thereby increase myocardial perfusion, improve cardiac function, and reduce damage to the heart.
“We are honored to have Professor Colombo actively participating in Miracor’s Scientific Advisory Council. He is a true pioneer in cardiology and his expertise is invaluable for the further establishment of PICSO therapy,” said Werner Braun, CEO of Miracor. “Miracor is dedicated to improving clinical outcome of patients with impaired cardiac function. We look forward to having Prof. Colombo contribute to this.”
Miracor Medical Systems makes technology for the treatment of severe cardiac diseases, aiming to improve short and long-term clinical outcome and reduce associated cost.
Colombo is director of the Cardiac Catheterization Laboratory at EMO GVM Centro Cuore Columbus and chief of invasive cardiology at San Raffaele Hospital, both in Milan, Italy, and visiting professor of Medicine at Columbia Medical Center in New York, N.Y. His expertise is in interventional cardiology and he has contributed significantly to today’s use of coronary stents and defined the role of intravascular ultrasound in this setting. In addition, his studies along with others have redefined adequate antiplatelet therapy after coronary stenting.
“It is with pleasure and excitement that I join the Scientific Advisory Council of Miracor,” said Colombo. “The PICSO impulse system is one of the most exciting new therapies in the area of acute myocardial infarction treatment and I also see a huge potential beyond this indication. I look forward to collaborating with the Council’s other members and to contributing significantly to the further establishment of PICSO in clinical practice and the investigation of its benefits in other indications.”
The PICSO (pressure-controlled intermittent coronary sinus occlusion) impulse system is designed for use during coronary revascularization procedures following myocardial infarction and other types of acute coronary syndrome to intermittently increase the pressure in the coronary venous system and thereby increase myocardial perfusion, improve cardiac function, and reduce damage to the heart.
“We are honored to have Professor Colombo actively participating in Miracor’s Scientific Advisory Council. He is a true pioneer in cardiology and his expertise is invaluable for the further establishment of PICSO therapy,” said Werner Braun, CEO of Miracor. “Miracor is dedicated to improving clinical outcome of patients with impaired cardiac function. We look forward to having Prof. Colombo contribute to this.”
Miracor Medical Systems makes technology for the treatment of severe cardiac diseases, aiming to improve short and long-term clinical outcome and reduce associated cost.